{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:00:33Z","timestamp":1790096433936,"version":"4.0.1"},"reference-count":82,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Card Fail Rev"],"abstract":"<jats:p>Congestion is central to heart failure (HF) but remains difficult to quantify. Carbohydrate antigen 125 (CA125), also known as mucin 16, released by mesothelial cells, captures two pathways relevant to HF: fluid overload and inflammation. This narrative review summarises biological mechanisms and clinical applications. Across acute and chronic settings, CA125 tracks systemic and right-sided congestion, complements natriuretic peptides and shows lower dependence on renal function. Higher levels identify patients at risk for death and readmission; in ambulatory HF with reduced ejection fraction it predicts events, while in HF with preserved ejection fraction its signal is strongest in congestion-dominant phenotypes. Serial testing mirrors decongestion and clinical course; CA125-guided care has reduced rehospitalisations and improved renal function measures in selected populations. Advantages, wide availability, standardisation and low cost, support use in practice. Key gaps include phenotype-specific threshold, sampling interval and integration into actionable algorithms. Overall, CA125 has moved from tumour marker to practical tool that refines congestion assessment, improves risk stratification and informs individualised therapy in contemporary HF care.<\/jats:p>","DOI":"10.15420\/cfr.2025.40","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:59:02Z","timestamp":1790092742000},"source":"Crossref","is-referenced-by-count":0,"title":["The Expanding Role of Carbohydrate Antigen 125 in Heart\u00a0Failure: From Tumour Marker to a Cornerstone of Heart Failure Management. An Updated Narrative Review"],"prefix":"10.15420","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0672-0696","authenticated-orcid":false,"given":"Agust\u00edn","family":"Fern\u00e1ndez-Cisnal","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02f3ts956","id-type":"ROR","asserted-by":"publisher"}],"name":"Parc Sanitari Sant Joan de D\u00e9u"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mollar","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00hpnj894","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Cl\u00ednico Universitario de Valencia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Mi\u00f1ana","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00hpnj894","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Cl\u00ednico Universitario de Valencia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"de la Espriella","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00hpnj894","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Cl\u00ednico Universitario de Valencia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Santas","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00hpnj894","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Cl\u00ednico Universitario de Valencia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Lorenzo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00hpnj894","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Cl\u00ednico Universitario de Valencia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar Romero","family":"Menor","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02f3ts956","id-type":"ROR","asserted-by":"publisher"}],"name":"Parc Sanitari Sant Joan de D\u00e9u"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1672-7119","authenticated-orcid":false,"given":"Julio","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00hpnj894","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Cl\u00ednico Universitario de Valencia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Sikaris KA. CA125: a test with a change of heart. Heart Lung Circ 2011;20:634\u201340. https:\/\/doi.org\/10.1016\/j.hlc.2010.08.001; PMID:\u00a020822954.","DOI":"10.1016\/j.hlc.2010.08.001"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Vizzardi E, D\u2019Aloia A, Pezzali N, et al. Long-term prognostic value of CA 125 serum levels in mild to moderate heart failure patients. J Card Fail 2012;18:68\u201373. https:\/\/doi.org\/10.1016\/j.cardfail.2011.09.012; PMID:\u00a022196844.","DOI":"10.1016\/j.cardfail.2011.09.012"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Vizzardi E, D\u2019Aloia A, Curnis A, Dei Cas L. Carbohydrate antigen 125: a new biomarker in heart failure. Cardiol Rev 2013;21:23\u20136. https:\/\/doi.org\/10.1097\/CRD.0b013e318265f58f; PMID:\u00a022735832.","DOI":"10.1097\/CRD.0b013e318265f58f"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Yilmaz MB, Nikolaou M, Cohen Solal A. Tumour biomarkers in heart failure: is there a role for CA-125? Eur J Heart Fail 2011;13:579\u201383. https:\/\/doi.org\/10.1093\/eurjhf\/hfr022; PMID:\u00a021525015.","DOI":"10.1093\/eurjhf\/hfr022"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Pan C, Zhou M, Jian Y, et al. CA125: an increasingly promising biomarker of heart failure. Curr Pharm Des 2021;27:3871\u201380. https:\/\/doi.org\/10.2174\/1381612827666210118122521; PMID:\u00a033461452.","DOI":"10.2174\/1381612827666210118122521"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Turk HM, Pekdemir H, Buyukberber S, et al. Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid. Tumour Biol 2003;24:172\u20135. https:\/\/doi.org\/10.1159\/000074425; PMID:\u00a014654710.","DOI":"10.1159\/000074425"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"N\u00e4gele H, Bahlo M, Klapdor R, et al. CA 125 and its relation to cardiac function. Am Heart J 1999;137:1044\u20139. https:\/\/doi.org\/10.1016\/S0002-8703(99)70360-1; PMID:\u00a010347329.","DOI":"10.1016\/S0002-8703(99)70360-1"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Faggiano P, D\u2019Aloia A, Brentana L, et al. Serum levels of different tumour markers in patients with chronic heart failure. Eur J Heart Fail 2005;7:57\u201361. https:\/\/doi.org\/10.1016\/j.ejheart.2004.04.009; PMID:\u00a015642532.","DOI":"10.1016\/j.ejheart.2004.04.009"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Shi C, van der Wal HH, Sillj\u00e9 HHW, et al. Tumour biomarkers: association with heart failure outcomes. J Intern Med 2020;288:207\u201318. https:\/\/doi.org\/10.1111\/joim.13053; PMID:\u00a032372544.","DOI":"10.1111\/joim.13053"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Mi\u00f1ana G, de la Espriella R, Mollar A, et al. Factors associated with plasma antigen carbohydrate 125 and amino-terminal pro-B-type natriuretic peptide concentrations in acute heart failure. Eur Heart J Acute Cardiovasc Care 2020;9:437\u201347. https:\/\/doi.org\/10.1177\/2048872620908033; PMID:\u00a032129669.","DOI":"10.1177\/2048872620908033"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Turgut O, Tandogan I, Yilmaz MB, et al. CA125 levels among patients with advanced heart failure: an emerging independent predictor for survival. Int J Cardiol 2010;145:71. https:\/\/doi.org\/10.1016\/j.ijcard.2009.04.030; PMID:\u00a019446349.","DOI":"10.1016\/j.ijcard.2009.04.030"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Huang F, Zhang K, Chen J, et al. Elevation of carbohydrate antigen 125 in chronic heart failure may be caused by mechanical extension of mesothelial cells from serous cavity effusion. Clin Biochem 2013;46:1694\u2013700. https:\/\/doi.org\/10.1016\/j.clinbiochem.2013.09.008; PMID:\u00a024060730.","DOI":"10.1016\/j.clinbiochem.2013.09.008"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Josa-Laorden C, Gim\u00e9nez-L\u00f3pez I, Rubio-Gracia J, et al. Prognostic value of measuring the diameter and inspiratory collapse of the inferior vena cava in acute heart failure. Rev Clin Esp (Barc) 2016;216:183\u201390 [in Spanish]. https:\/\/doi.org\/10.1016\/j.rce.2015.11.012; PMID:\u00a026774759.","DOI":"10.1016\/j.rceng.2015.11.005"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Rubio-Gracia J, Crespo-Aznarez S, De la Espriella R, et al. Utility of plasma CA125 as a proxy of intra-abdominal pressure in patients with acute heart failure. Eur Heart J Acute Cardiovasc Care 2022;11:453\u201360. https:\/\/doi.org\/10.1093\/ehjacc\/zuac046; PMID:\u00a035512321.","DOI":"10.1093\/ehjacc\/zuac046"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Kosar F, Aksoy Y, Ozguntekin G, et al. Relationship between cytokines and tumour markers in patients with chronic heart failure. Eur J Heart Fail 2006;8:270\u20134. https:\/\/doi.org\/10.1016\/j.ejheart.2005.09.002; PMID:\u00a016309955.","DOI":"10.1016\/j.ejheart.2005.09.002"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"N\u00fa\u00f1ez J, de la Espriella R, Mi\u00f1ana G, et al. Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review. Eur J Heart Fail 2021;23:1445\u201357. https:\/\/doi.org\/10.1002\/ejhf.2295; PMID:\u00a034241936.","DOI":"10.1002\/ejhf.2295"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"N\u00fa\u00f1ez J, Mi\u00f1ana G, N\u00fa\u00f1ez E, et al. Clinical utility of antigen carbohydrate 125 in heart failure. Heart Fail Rev 2014;19:575\u201384. https:\/\/doi.org\/10.1007\/s10741-013-9402-y; PMID:\u00a023925386.","DOI":"10.1007\/s10741-013-9402-y"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Zeillemaker AM, Verbrugh HA, Hoynck Van Papendrecht AA, Leguit P. CA 125 secretion by peritoneal mesothelial cells. J Clin Pathol 1994;47:263\u20135. https:\/\/doi.org\/10.1136\/jcp.47.3.263; PMID:\u00a08163699.","DOI":"10.1136\/jcp.47.3.263"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Stanciu AE, Stanciu MM, Vatasescu RG. NT-proBNP and CA 125 levels are associated with increased pro-inflammatory cytokines in coronary sinus serum of patients with chronic heart failure. Cytokine 2018;111:13\u20139. https:\/\/doi.org\/10.1016\/j.cyto.2018.07.037; PMID:\u00a030098475.","DOI":"10.1016\/j.cyto.2018.07.037"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Pandhi P, ter Maaten JM, Anker SD, et al. Pathophysiologic processes and novel biomarkers associated with congestion in heart failure. JACC Heart Fail 2022;10:623\u201332. https:\/\/doi.org\/10.1016\/j.jchf.2022.05.013; PMID:\u00a036049813.","DOI":"10.1016\/j.jchf.2022.05.013"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Feng R, Zhang Z, Fan Q. Carbohydrate antigen 125 in congestive heart failure: ready for clinical application? Front Oncol 2023;13:1161723. https:\/\/doi.org\/10.3389\/fonc.2023.1161723; PMID:\u00a038023127.","DOI":"10.3389\/fonc.2023.1161723"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Eiras S, de la Espriella R, Fu X, et al. Carbohydrate antigen 125 on epicardial fat and its association with local inflammation and fibrosis-related markers. J Transl Med 2024;22:619. https:\/\/doi.org\/10.1186\/s12967-024-05351-z; PMID:\u00a038961436.","DOI":"10.1186\/s12967-024-05351-z"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"D\u2019Aloia A, Faggiano P, Aurigemma G, et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol 2003;41:1805\u201311. https:\/\/doi.org\/10.1016\/S0735-1097(03)00311-5; PMID:\u00a012767668.","DOI":"10.1016\/S0735-1097(03)00311-5"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Kouris NT, Zacharos ID, Kontogianni DD, et al. The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail 2005;7:199\u2013203. https:\/\/doi.org\/10.1016\/j.ejheart.2004.07.015; PMID:\u00a015701467.","DOI":"10.1016\/j.ejheart.2004.07.015"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Duman D, Palit F, Simsek E, Bilgehan K. Serum carbohydrate antigen 125 levels in advanced heart failure: relation to B-type natriuretic peptide and left atrial volume. Eur J Heart Fail 2008;10:556\u20139. https:\/\/doi.org\/10.1016\/j.ejheart.2008.04.012; PMID:\u00a018501671.","DOI":"10.1016\/j.ejheart.2008.04.012"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Gay\u00e1n Ord\u00e1s J, Nu\u00f1ez J, Bascompte Claret R, et al. Usefulness of antigen carbohydrate 125 and N-terminal pro-B-type natriuretic peptide for assessing congestion in chronic heart failure: insights from the CARDIOREN registry. Cardiorenal Med 2024;14:543\u201355. https:\/\/doi.org\/10.1159\/000541324; PMID:\u00a039236691.","DOI":"10.1159\/000541324"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"N\u00fa\u00f1ez-Mar\u00edn G, de la Espriella R, Santas E, et al. CA125 but not NT-proBNP predicts the presence of a congestive intrarenal venous flow in patients with acute heart failure. Eur Heart J Acute Cardiovasc Care 2021;10:475\u201383. https:\/\/doi.org\/10.1093\/ehjacc\/zuab022; PMID:\u00a033829233.","DOI":"10.1093\/ehjacc\/zuab022"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Zhuang J, Faggiano P, Li Q, et al. Insights into the clinical implications of carbohydrate antigen 125 as a biomarker of heart failure: a meta-analysis and systematic review of published studies. J Cardiovasc Med (Hagerstown) 2014;15:864\u201372. https:\/\/doi.org\/10.2459\/JCM.0000000000000051; PMID:\u00a025353973.","DOI":"10.2459\/JCM.0000000000000051"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Chen YX, Wang XQ, Fang CF, et al. Value of BNP and tumour marker CA125 in patients with heart failure. Acta Cardiol 2008;63:501\u20136. https:\/\/doi.org\/10.2143\/AC.63.4.2033050; PMID:\u00a018795589.","DOI":"10.2143\/AC.63.4.2033050"},{"key":"ref29","unstructured":"Mir\u00f3 \u00d2, N\u00fa\u00f1ez J, Trull\u00e0s JC, et al. Carbohydrate antigen 125 determined on arrival at the emergency department correlates with severity of decompensation and adverse outcomes in patients with acute heart failure. Intern Emerg Med 2025;21:231\u201341. https:\/\/doi.org\/10.1007\/s11739-025-03932-4; PMID:\u00a040325282."},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"de Juan Bagud\u00e1 J, Severo S\u00e1nchez A, de la Espriella R, et al. Evaluation of carbohydrate antigen 125 in heart failure with preserved ejection fraction diagnosis. Heart 2026;112:223\u201330. https:\/\/doi.org\/10.1136\/heartjnl-2025-326053; PMID:\u00a040877030.","DOI":"10.1136\/heartjnl-2025-326053"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"N\u00fa\u00f1ez J, N\u00fa\u00f1ez E, Consuegra L, et al. Carbohydrate antigen 125: an emerging prognostic risk factor in acute heart failure? Heart (Br Card Soc) 2007;93:716\u201321. https:\/\/doi.org\/10.1136\/hrt.2006.096016; PMID:\u00a017164487.","DOI":"10.1136\/hrt.2006.096016"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Li KHC, Gong M, Li G, et al. Cancer antigen-125 and outcomes in acute heart failure: a systematic review and meta-analysis. Heart Asia 2018;10:e011044. https:\/\/doi.org\/10.1136\/heartasia-2018-011044; PMID:\u00a030402141.","DOI":"10.1136\/heartasia-2018-011044"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"N\u00fa\u00f1ez J, Bay\u00e9s-Gen\u00eds A, Revuelta-L\u00f3pez E, et al. Optimal carbohydrate antigen 125 cutpoint for identifying low-risk patients after admission for acute heart failure. Rev Esp Cardiol (Engl Ed) 2022;75:316\u201324. https:\/\/doi.org\/10.1016\/j.rec.2021.02.002; PMID:\u00a033745912.","DOI":"10.1016\/j.rec.2021.02.002"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"N\u00fa\u00f1ez J, Bay\u00e9s-Gen\u00eds A, Revuelta-L\u00f3pez E, et al. Clinical role of CA125 in worsening heart failure: a BIOSTAT-CHF study subanalysis. JACC Heart Fail 2020;8:386\u201397. https:\/\/doi.org\/10.1016\/j.jchf.2019.12.005; PMID:\u00a032171764.","DOI":"10.1016\/j.jchf.2019.12.005"},{"key":"ref35","unstructured":"Davutoglu V, Yildirim C, Kucukaslan H, et al. Prognostic value of pleural effusion, CA-125 and NT-proBNP in patients with acute decompensated heart failure. Kardiol Pol 2010;68:771\u20138. PMID:\u00a020648434."},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"N\u00fa\u00f1ez J, Sanchis J, Bod\u00ed V, et al. Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure. Eur Heart J 2010;31:1752\u201363. https:\/\/doi.org\/10.1093\/eurheartj\/ehq142; PMID:\u00a020501480.","DOI":"10.1093\/eurheartj\/ehq142"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Truong CM, Do NHN, Chau HN, Thai TT. Prognostic value of carbohydrate antigen 125 combined with N-terminal pro B-type natriuretic peptide in patients with acute heart failure: a prospective cohort study in Vietnam. BMC Cardiovasc Disord 2025;25:523. https:\/\/doi.org\/10.1186\/s12872-025-04994-0; PMID:\u00a040681999.","DOI":"10.1186\/s12872-025-04994-0"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Docherty KF, McDowell K, Welsh P, et al. Association of carbohydrate antigen 125 on the response to dapagliflozin in patients with heart failure. J Am Coll Cardiol 2023;82:142\u201357. https:\/\/doi.org\/10.1016\/j.jacc.2023.05.011; PMID:\u00a037407113.","DOI":"10.1016\/j.jacc.2023.05.011"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Ferreira JP, Packer M, Sattar N, et al. Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: the EMPEROR programme. Eur J Heart Fail 2024;26:788\u2013802. https:\/\/doi.org\/10.1002\/ejhf.3166; PMID:\u00a038439582.","DOI":"10.1002\/ejhf.3166"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Menghoum N, Badii MC, Deltombe M, et al. Carbohydrate antigen 125: a useful marker of congestion, fibrosis, and prognosis in heart failure with preserved ejection fraction. ESC Heart Fail 2024;11:1493\u2013505. https:\/\/doi.org\/10.1002\/ehf2.14699; PMID:\u00a038339764.","DOI":"10.1002\/ehf2.14699"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Hung CL, Hung TC, Liu CC, et al. Relation of carbohydrate antigen-125 to left atrial remodeling and its prognostic usefulness in patients with heart failure and preserved left ventricular ejection fraction in women. Am J Cardiol 2012;110:993\u20131000. https:\/\/doi.org\/10.1016\/j.amjcard.2012.05.030; PMID:\u00a022728006.","DOI":"10.1016\/j.amjcard.2012.05.030"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Mi\u00f1ana G, de la Espriella R, Palau P, et al. Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction. Sci Rep 2022;12:1344. https:\/\/doi.org\/10.1038\/s41598-022-05328-2; PMID:\u00a035079082.","DOI":"10.1038\/s41598-022-05328-2"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"N\u00fa\u00f1ez-Mar\u00edn G, Palau P, Dom\u00ednguez E, et al. CA125 outperforms NT-proBNP in the prediction of maximum aerobic capacity in heart failure with preserved ejection fraction and kidney dysfunction. Clin Kidney J 2024;17:sfae199. https:\/\/doi.org\/10.1093\/ckj\/sfae199; PMID:\u00a039135938.","DOI":"10.1093\/ckj\/sfae199"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Ll\u00e0cer P, N\u00fa\u00f1ez J, Manzano L, et al. Carbohydrate antigen 125 (CA125) as a prognostic marker in the elderly with acute heart failure and preserved ejection fraction. Med Clin (Barc) 2022;159:164\u201370 [in Spanish]. https:\/\/doi.org\/10.1016\/j.medcli.2021.09.032; PMID:\u00a034895749.","DOI":"10.1016\/j.medcle.2021.09.032"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"N\u00fa\u00f1ez J, Rabinovich GA, Sandino J, et al. Prognostic value of the interaction between galectin-3 and antigen carbohydrate 125 in acute heart failure. PLoS One 2015;10:e0122360. https:\/\/doi.org\/10.1371\/journal.pone.0122360; PMID:\u00a025875367.","DOI":"10.1371\/journal.pone.0122360"},{"key":"ref46","unstructured":"Gruson D, Maisin D, Pouleur AC, et al. CA125, galectin-3 and FGF-23 are interrelated in heart failure with reduced ejection fraction. EJIFCC 2023;34:103\u20139. PMID:\u00a037455845."},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Revuelta-L\u00f3pez E, De La Espriella R, Mi\u00f1ana G, et al. The modulating effect of circulating carbohydrate antigen 125 on ST2 and long-term recurrent morbidity burden. Sci Rep 2025;15:1905. https:\/\/doi.org\/10.1038\/s41598-024-84622-7; PMID:\u00a039809935.","DOI":"10.1038\/s41598-024-84622-7"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Xie YT, Dang Y, Zhang FF, et al. Combination of serum TIMP-3, CA125, and NT-proBNP in predicting ventricular remodeling in patients with heart failure following acute myocardial infarction. Cardiovasc Diagn Ther 2020;10:1184\u201391. https:\/\/doi.org\/10.21037\/cdt-20-399; PMID:\u00a033224742.","DOI":"10.21037\/cdt-20-399"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Ll\u00e0cer P, Croset F, de la Espriella R, et al. The impact of hypoalbuminemia on the long-term prognosis of patients with acute heart failure: the modifying role of carbohydrate antigen 125. Eur J Intern Med 2025;133:71\u20137. https:\/\/doi.org\/10.1016\/j.ejim.2024.12.024; PMID:\u00a039753436.","DOI":"10.1016\/j.ejim.2024.12.024"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Vilella R, Gonz\u00e1lez-V\u00edlchez F, Guerrero Cervera B, et al. Predictive factors of non-elevation of carcinoembryonic antigen 125 in acute heart failure. Life (Basel) 2025;15:494. https:\/\/doi.org\/10.3390\/life15030494; PMID:\u00a040141838.","DOI":"10.3390\/life15030494"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"N\u00fa\u00f1ez J, N\u00fa\u00f1ez E, Bay\u00e9s-Gen\u00eds A, et al. Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute heart failure. Eur Heart J Acute Cardiovasc Care 2017;6:685\u201396. https:\/\/doi.org\/10.1177\/2048872616649757; PMID:\u00a027199489.","DOI":"10.1177\/2048872616649757"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"N\u00fa\u00f1ez J, N\u00fa\u00f1ez E, Sanchis J, et al. Antigen carbohydrate 125 and brain natriuretic peptide serial measurements for risk stratification following an episode of acute heart failure. Int J Cardiol 2012;159:21\u20138. https:\/\/doi.org\/10.1016\/j.ijcard.2011.02.001; PMID:\u00a021367474.","DOI":"10.1016\/j.ijcard.2011.02.001"},{"key":"ref53","unstructured":"Mi\u00f1ana Escriv\u00e1 G, N\u00fa\u00f1ez J, Sanchis J, et al. Carbohydrate antigen 125 serial measurements after an admission for acute heart failure and risk of early readmission. Med Clin (Barc) 2012;139:479\u201386 [in Spanish]. https:\/\/doi.org\/10.1016\/j.medcli.2011.05.029; PMID:\u00a022093405."},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Louren\u00e7o P, Cunha FM, Elias C, et al. CA-125 variation in acute heart failure: a single-centre analysis. ESC Heart Fail 2022;9:1018\u201326. https:\/\/doi.org\/10.1002\/ehf2.13758; PMID:\u00a034989167.","DOI":"10.1002\/ehf2.13758"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"N\u00fa\u00f1ez J, Ll\u00e0cer P, Bertomeu-Gonz\u00e1lez V, et al. Carbohydrate antigen-125-guided therapy in acute heart failure: CHANCE-HF: a randomized study. JACC Heart Fail 2016;4:833\u201343. https:\/\/doi.org\/10.1016\/j.jchf.2016.06.007; PMID:\u00a027522630.","DOI":"10.1016\/j.jchf.2016.06.007"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"N\u00fa\u00f1ez J, Ll\u00e0cer P, Garc\u00eda-Blas S, et al. CA125-guided diuretic treatment versus usual care in patients with acute heart failure and renal dysfunction. Am J Med 2020;133:370\u2013380. https:\/\/doi.org\/10.1016\/j.amjmed.2019.07.041; PMID:\u00a031422111.","DOI":"10.1016\/j.amjmed.2019.07.041"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"de la Espriella R, Mi\u00f1ana G, Santas E, et al. Effects of empagliflozin on CA125 trajectory in patients with chronic congestive heart failure. Int J Cardiol 2021;339:102\u20135. https:\/\/doi.org\/10.1016\/j.ijcard.2021.06.045; PMID:\u00a034216708.","DOI":"10.1016\/j.ijcard.2021.06.045"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Mi\u00f1ana G, de la Espriella R, Lorenzo-Hern\u00e1ndez M, et al. Changes in antigen carbohydrate 125 in patients receiving dapagliflozin following an admission for acute heart failure. Cardiorenal Med 2025;15:122\u201332. https:\/\/doi.org\/10.1159\/000543417; PMID:\u00a039778554.","DOI":"10.1159\/000543417"},{"key":"ref59","unstructured":"Amiguet M, Palau P, Dom\u00ednguez E, et al. Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction. Sci Rep 2023;13:10591. https:\/\/doi.org\/10.1038\/s41598-023-37491-5; PMID:\u00a037391470."},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"N\u00fa\u00f1ez J, Heredia R, Pay\u00e1 A, et al. Use of acetazolamide in the treatment of patients with refractory congestive heart failure. Cardiovasc Ther 2018;36:e12465. https:\/\/doi.org\/10.1111\/1755-5922.12465; PMID:\u00a030191652.","DOI":"10.1111\/1755-5922.12465"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"N\u00fa\u00f1ez J, Gonz\u00e1lez M, Mi\u00f1ana G, et al. Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure. Eur J Heart Fail 2012;14:540\u20138. https:\/\/doi.org\/10.1093\/eurjhf\/hfs013; PMID:\u00a022327061.","DOI":"10.1093\/eurjhf\/hfs013"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Lorenzo M, Palau P, Ll\u00e0cer P, et al. Clinical utility of antigen carbohydrate 125 for planning the optimal length of stay in acute heart failure. Eur J Intern Med 2021;92:94\u20139. https:\/\/doi.org\/10.1016\/j.ejim.2021.05.037; PMID:\u00a034130879.","DOI":"10.1016\/j.ejim.2021.05.037"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"N\u00fa\u00f1ez J, N\u00fa\u00f1ez E, Mi\u00f1ana G, et al. Differential mortality association of loop diuretic dosage according to blood urea nitrogen and carbohydrate antigen 125 following a hospitalization for acute heart failure. Eur J Heart Fail 2012;14:974\u201384. https:\/\/doi.org\/10.1093\/eurjhf\/hfs090; PMID:\u00a022700856.","DOI":"10.1093\/eurjhf\/hfs090"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"de la Espriella R, Bay\u00e9s-Gen\u00eds A, Ll\u00e0cer P, et al. Prognostic value of NT-proBNP and CA125 across glomerular filtration rate categories in acute heart failure. Eur J Intern Med 2022;95:67\u201373. https:\/\/doi.org\/10.1016\/j.ejim.2021.08.024; PMID:\u00a034507853.","DOI":"10.1016\/j.ejim.2021.08.024"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Soler M, Mi\u00f1ana G, Santas E, et al. CA125 outperforms NT-proBNP in acute heart failure with severe tricuspid regurgitation. Int J Cardiol 2020;308:54\u20139. https:\/\/doi.org\/10.1016\/j.ijcard.2020.03.027; PMID:\u00a032209267.","DOI":"10.1016\/j.ijcard.2020.03.027"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Sahin A, Kaya H, Avci O. Cancer antigen-125 is a predictor of mortality in patients with pulmonary arterial hypertension. Clin Biochem 2021;89:58\u201362. https:\/\/doi.org\/10.1016\/j.clinbiochem.2020.12.010; PMID:\u00a033382999.","DOI":"10.1016\/j.clinbiochem.2020.12.010"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Buend\u00eda Fuentes F, Jover Pastor P, Arnau Vives M\u00c1, et al. CA125: a new biomarker in patients with Fontan circulation. Rev Esp Cardiol (Engl Ed) 2023;76:112\u201320. https:\/\/doi.org\/10.1016\/j.rec.2022.05.029; PMID:\u00a035870779.","DOI":"10.1016\/j.rec.2022.05.029"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Zhang J, Li W, Xiao J, et al. Prognostic significance of carbohydrate antigen 125 in stage D heart failure. BMC Cardiovasc Disord 2023;23:108. https:\/\/doi.org\/10.1186\/s12872-023-03139-5; PMID:\u00a036841766.","DOI":"10.1186\/s12872-023-03139-5"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Monteiro S, Franco F, Costa S, et al. Prognostic value of CA125 in advanced heart failure patients. Int J Cardiol 2010;140:115\u20138. https:\/\/doi.org\/10.1016\/j.ijcard.2008.11.023; PMID:\u00a019285353.","DOI":"10.1016\/j.ijcard.2008.11.023"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Nan Y, Tiemuerniyazi X, Chen L, et al. Prognostic value of carbohydrate antigen 125 in patients undergoing surgical left ventricular reconstruction. Int J Cardiol 2023;371:377\u201383. https:\/\/doi.org\/10.1016\/j.ijcard.2022.09.077; PMID:\u00a036208679.","DOI":"10.1016\/j.ijcard.2022.09.077"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Vilella R, S\u00e1nchez-L\u00e1zaro I, Aguado C, et al. Utility of the biomarker CA125 in the diagnosis of cellular rejection in allogeneic heart transplantation. Transplant Proc 2021;53:2721\u20133. https:\/\/doi.org\/10.1016\/j.transproceed.2021.07.058; PMID:\u00a034600758.","DOI":"10.1016\/j.transproceed.2021.07.058"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Husser O, N\u00fa\u00f1ez J, N\u00fa\u00f1ez E, et al. Tumor marker carbohydrate antigen 125 predicts adverse outcome after transcatheter aortic valve implantation. JACC Cardiovasc Interv 2013;6:487\u201396. https:\/\/doi.org\/10.1016\/j.jcin.2013.02.006; PMID:\u00a023702013.","DOI":"10.1016\/j.jcin.2013.02.006"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Romeo FJ, Seropian IM, Chiabrando JG, et al. Additive prognostic value of carbohydrate antigen-125 over frailty in patients undergoing transcatheter aortic valve replacement. Catheter Cardiovasc Interv 2021;97:E263\u201373. https:\/\/doi.org\/10.1002\/ccd.29067; PMID:\u00a032597028.","DOI":"10.1002\/ccd.29067"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Rheude T, Pellegrini C, Schmid H, et al. Comparison of carbohydrate antigen 125 and N-terminal pro-brain natriuretic peptide for risk prediction after transcatheter aortic valve implantation. Am J Cardiol 2018;121:461\u20138. https:\/\/doi.org\/10.1016\/j.amjcard.2017.11.020; PMID:\u00a029306485.","DOI":"10.1016\/j.amjcard.2017.11.020"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Blas S, Pernias V, Gonz\u00e1lez D\u2019Gregorio J, et al. Carbohydrate antigen 125-guided pre-TAVI medical optimization: impact on quality of life and clinical outcomes. Rev Esp Cardiol (Engl Ed) 2024;77:750\u20138. https:\/\/doi.org\/10.1016\/j.rec.2024.01.002; PMID:\u00a038311024.","DOI":"10.1016\/j.rec.2024.01.002"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Falc\u00e3o FJA, Oliveira FRA, Cantarelli F, et al. Carbohydrate antigen 125 predicts pulmonary congestion in patients with ST-segment elevation myocardial infarction. Braz J Med Biol Res 2019;52:e9124. https:\/\/doi.org\/10.1590\/1414-431X20199124; PMID:\u00a031826182.","DOI":"10.1590\/1414-431x20199124"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Falc\u00e3o F, Oliveira F, Cantarelli F, et al. Carbohydrate antigen 125 for mortality risk prediction following acute myocardial infarction. Sci Rep 2020;10:11016. https:\/\/doi.org\/10.1038\/s41598-020-67548-8; PMID:\u00a032620821.","DOI":"10.1038\/s41598-020-67548-8"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Yndigegn T, Gu T, Grufman H, et al. Elevated carbohydrate antigen 125 (CA125) is associated with incident heart failure and mortality in acute coronary syndrome. ESC Heart Fail 2024;11:4325\u201334. https:\/\/doi.org\/10.1002\/ehf2.15037; PMID:\u00a039219224.","DOI":"10.1002\/ehf2.15037"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Cordero A, Velasco I, Flores E, et al. Heart failure biomarkers and prediction of early left ventricle remodeling after acute coronary syndromes. Clin Biochem 2024;131\u2013132:110814. https:\/\/doi.org\/10.1016\/j.clinbiochem.2024.110814; PMID:\u00a039218335.","DOI":"10.1016\/j.clinbiochem.2024.110814"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Wu B, Shi J, Yu F, et al. Association of cancer antigen 125 with long-term prognosis in light-chain cardiorenal amyloidosis. Cardiorenal Med 2023;13:19\u201325. https:\/\/doi.org\/10.1159\/000527442; PMID:\u00a036215974.","DOI":"10.1159\/000527442"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Yoon JY, Yang DH, Cho HJ, et al. Serum levels of carbohydrate antigen 125 in combination with N-terminal pro-brain natriuretic peptide in patients with acute decompensated heart failure. Korean J Intern Med 2019;34:811\u20138. https:\/\/doi.org\/10.3904\/kjim.2017.313; PMID:\u00a030616330.","DOI":"10.3904\/kjim.2017.313"}],"container-title":["Cardiac Failure Review"],"original-title":[],"link":[{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2025.40","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:59:25Z","timestamp":1790092765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2025.40"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":82,"URL":"https:\/\/doi.org\/10.15420\/cfr.2025.40","relation":{},"ISSN":["2057-7540","2057-7559"],"issn-type":[{"value":"2057-7540","type":"print"},{"value":"2057-7559","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"e31"}}